

Special Issue

Steps towards the Clinics in Spatially Fractionated Radiation Therapy

Message from the Guest Editor

Despite the technical optimization of radiation oncology, treatment outcomes for certain cancer types remain dismal, and there is a need for disruptive new developments. Microbeam radiation therapy is one of these developments that developed in the niche around third-generation synchrotrons. It poses extreme demands on technology, patient safety, and dosimetry, and after decades of research still offers many open biomedical questions. At this time, technology and the availability of compact radiation sources in MRT have matured, and the first clinical trials seem to be in reach. This Special Issue is dedicated to the remaining issues on the way of MRT to the clinics, looking at radiation technology, dosimetry, treatment planning, and preclinical studies. Related original research articles or reviews are welcome.

Guest Editor

Dr. Stefan Bartzsch

Klinikum rechts der Isar der, Technischen Universität München,
Munich, Germany

Deadline for manuscript submissions

closed (10 September 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/126465

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)